Results 101 to 110 of about 13,064 (207)
EPHA2 Is a Therapeutic Target in NSCLC [PDF]
Abstract EPHA2 depletion or small molecule inhibition promotes apoptosis in preclinical models of NSCLC.
openaire +1 more source
1.Supplementary Materials and Methods; Supplementary Table S1-4; Supplementary Figure S1-8. Table S1. The clinicopathological characteristics of 184 patients with NPC. Table S2. The primers used for the amplification of the three genes by qRT-PCR.
Zheng-Zheng Yu (14944567) +13 more
core +1 more source
EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes
EphA2 (Eck) is a tyrosine kinase receptor that is overexpressed in several human cancers such as breast, colon, lung, prostate, gastric carcinoma, and metastatic melanoma but not in nonmalignant counterparts.
Cornet, S. +8 more
core
Theranostics using ⁸⁹Zr/¹⁷⁷Lu-labeled antibody targeting erythropoietin-producing hepatocellular A2 (EphA2) [PDF]
The version of record of this article, first published in European Journal of Nuclear Medicine and Molecular Imaging, is available online at Publisher’s website: https://doi.org/10.1007/s00259-025-07139-9.Purpose: Erythropoietin-producing hepatocellular ...
Kobayashi, Takanori +10 more
core +1 more source
EphA2 specific chimeric antigen receptor engineered T cells for the treatment of prostate cancer
Erythropoietin-producing hepatocyte receptor A2 (EphA2) is an attractive target for immunotherapy due to its high expression in a variety of solid tumors including prostate cancer.
Miaomiao Zhang +8 more
doaj +1 more source
Despite accumulating evidence revealing susceptibility genes for age-related cataract, its pathophysiology leading to visual impairment at the cellular and molecular level remains poorly understood.
Jin Yang +6 more
doaj +1 more source
Serum Exosomal EphA2 is a Prognostic Biomarker in Patients with Pancreatic Cancer
Qian Wei, Ze Li, Honglei Feng, Li Ren Department of Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research ...
Wei Q, Li Z, Feng H, Ren L
doaj
THE EPHA2/EPHRIN-A1 AXIS REGULATES HOST-TUMOR INTERACTIONS
Despite significant advancements in cancer research, prevention, and therapeutics, cancer remains a major public health problem. The EphA2 receptor tyrosine kinase and ephrin-A1 ligand signaling axis has long been implicated in solid cancers, including ...
Shiuan, Eileen Fong
core
Effect of EphA2 Transfection on Proliferation and Invasion Activities of Prostate Cancer LNcap Cells [PDF]
目的 本实验试图用外源基因EphA2转染LNcap细胞,探讨EphA2对前列腺癌LNcap细胞增殖、迁移、侵袭活性的影响。 方法 构建重组pcDNA3.1(+)-EphA2,转染LNcap细胞并经G418筛选出稳定转染株。实验分3组:(1)空白对照组:激素依赖性前列腺癌LNcap;(2)阴性对照组:转染空载质粒pcDNA3.1(+)的LNcap-pcDNA3.1(+);(3)实验组:转染pcDNA3.1(+)-EphA2的LNcap稳定表达株LNcap-EphA2。RT ...
黄燕
core
Serum EphA2 as a Promising Biomarker for the Early Detection and Diagnosis of Colorectal Cancer
Background: EphA2, a receptor-type tyrosine kinase, is overexpressed in several cancers, including colorectal cancer (CRC), and can be detected as soluble EphA2 in serum.
Shunsuke Sakuraba +4 more
doaj +1 more source

